21 DECEMBER 2017
ImmuPharma PLC
("ImmuPharma" or the "Company")
Last patient completes dosing in Lupuzor™ Pivotal Phase III Study
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to confirm that the last patient has completed dosing within the 52-week, randomised, double-blinded, Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto-immune disease.
Study summary as at 21 December 2017
· 200 patients successfully recruited and randomised (dosed)
· Last patient successfully completed dosing
· Continued robust safety record which remains consistent with Lupuzor™'s product profile as shown in its previous Phase IIb study
· Top line results remain on track to be reported in Q1 2018
Commenting on the trial update, Tim McCarthy, Chairman of ImmuPharma said: "We are delighted to announce this significant milestone that all patients have now completed dosing in this pivotal Phase III trial for Lupuzor™. Importantly we continue to see robust safety and we look forward with continued confidence to reporting top line results of the study in Q1 2018."
For more information on the trial please visit: https://clinicaltrials.gov/ct2/show/NCT02504645
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.
For further information please contact:
ImmuPharma plc (www.immupharma.org) |
+ 44 (0) 20 7152 4080 |
Tim McCarthy, Chairman |
|
Lisa Baderoon, Head of Investor Relations Twitter: @immupharma |
+ 44 (0) 7721 413496 |
|
|
Northland Capital Partners Limited (Joint Broker) Patrick Claridge, David Hignell, Jamie Spotswood, Corporate Finance Rob Rees, Corporate Broking |
+44 (0)20 3861 6625 |
|
|
|
|
